60 Binney St
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
277 articles with bluebird bio
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb
bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
bluebird bio, Inc. announced updated results from the completed Phase 1/2 Northstar study, and new data from the Phase 3 Northstar-2 and Phase 3 Northstar-3 clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia, at the 24th European Hematology Association Congress in Amsterdam, the Netherlands.
Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.
bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval
bluebird bio, Inc. announced that the company will host a live webcast to review new data presented at the European Hematology Association Annual Meeting, and to discuss the approval of ZYNTEGLO® on Friday, June 14 at 8:00 a.m. ET.
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)
bluebird bio, Inc. announced that the Company will hold a conference call to discuss data presented at the European Hematology Association Annual Meeting on Friday, June 14 at 8:00 am ET.
bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT
bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies
New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia
bluebird bio, Inc. announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY.
Company hosting Analyst Day on May 9, 2019 focused on research and commercial strategies
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine
The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects.
bluebird bio, Inc., has appointed Joanne Smith-Farrell, Ph.D., to chief business officer.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
First gene therapy recommended for approval in the EU for TDT
A third party press release was issued stating that the EMA issued an approval for the conditional Marketing Authorization Application for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia.
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina
Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio's capabilities to manufacture products for clinical development and commercial supply
The manufacturing plant will produce lentiviral vector for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.